Drug-Resistant Ringworm Fungus Spreads to 29 Countries as Cases Surge
Drug-resistant ringworm caused by the fungus Trichophyton indotineae has spread to 29 countries, with annual laboratory identifications surging nearly threefold over a three-year window, according to data published in the Centers for Disease Control and Prevention journal Emerging Infectious Diseases. Researchers analyzing international laboratory samples recorded 3,399 identifications of the pathogen from 2022 through 2025, revealing an expanding global footprint that routinely evades standard terbinafine treatments.
- Annual identifications of drug-resistant ringworm rose from 237 in 2022 to 1,692 in 2025, marking a sharp three-fold increase across reporting intervals.
- Europe accounted for 89.4% of reported laboratory spectra due to higher testing density, while regions like Africa, India, and the Middle East show severe underreporting from limited mass spectrometry availability.
- Clinical presentations involve extensive, itchy, and persistent rashes that fail standard over-the-counter or oral antifungal regimens, requiring advanced molecular testing for definitive diagnosis.
Global Spread and Rising Infection Metrics
The longitudinal study tracked laboratory submissions from 183 participating users across 29 nations, capturing a significant expansion of Trichophyton indotineae. Annual detections escalated from 237 cases in 2022 to 1,692 cases by the close of 2025. Investigators highlighted that the pathogen demonstrates clear resistance to terbinafine, a frontline oral and topical medication traditionally relied upon to clear dermatophyte infections. While the fungus was initially identified in South Asia—with historical tracking pointing to outbreaks in India—it has established transmission cycles throughout urban and rural settings across Western nations.
Europe represented 63.8% of participating laboratory users and generated 89.4% of the reported spectra. Conversely, regions where the fungus is known to circulate widely, including Africa, India, and the Middle East, yielded few or zero detections in the dataset. Public health authorities attribute these discrepancies directly to limited access to mass spectrometry and specialized molecular identification tools required to differentiate T. indotineae from typical dermatophytes.
Clinical Presentation and Pathogenesis Challenges
Standard ringworm typically manifests as localized, circular, scaly lesions that resolve quickly with conventional topical antifungals. By contrast, infections driven by T. indotineae present as widespread, highly inflammatory, and persistent rashes covering large expanses of the body, including the face, groin, and trunk. Patients frequently experience prolonged morbidity because standard clinical protocols fail to clear the pathogen.
Epidemiological tracking indicates the strain entered the United States in 2023, when clinicians identified two unrelated patients in New York City exhibiting recalcitrant infections that did not respond to oral terbinafine. Subsequent surveillance by public health agencies confirmed the strain across 11 states.
Surveillance and Public Health Implications
The CDC currently tracks multiple emerging antifungal-resistant threats, including T. indotineae, terbinafine-resistant Trichophyton rubrum, and TMVII. Because the fungus spreads easily through direct skin contact, contaminated clothing, bedding, and shared surfaces in athletic facilities, researchers emphasize the role of international travel in accelerating cross-border transmission. Public health agencies advise clinicians to maintain a high index of suspicion for drug resistance whenever standard ringworm treatments fail over a multi-month period.
Addressing this international challenge requires expanded laboratory surveillance and broader integration of advanced diagnostic assays into clinical microbiology workflows. Health authorities stress that robust screening protocols remain vital for tracking transmission pathways and protecting vulnerable populations from prolonged infection cycles.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.